The above data support a pivotal role for COX-2 expression in tumors treated with irradiation and thus justify studies to evaluate the clinical application of targeting COX-2 in patients undergoing radiation therapy as a treatment for prostate cancer. Here, PTGS2 is linked to prostate carcinoma.